Page last updated: 2024-12-07
terpentecin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
terpentecin: isolated from strain MF730-N6; active against leukemia L-1210 and Ehrlich ascites carcinoma [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 127568 |
| CHEBI ID | 50301 |
| SCHEMBL ID | 93525 |
| MeSH ID | M0137824 |
Synonyms (16)
| Synonym |
|---|
| oxiraneacetaldehyde, 2-(1-hydroxy-2-(1,2,3,4,4a,7,8,8a-octahydro-3-hydroxy-1,2,4a,5-tetramethyl-4-oxo-1-naphthalenyl)ethyl)-alpha-oxo-, (1-alpha(s*(r*)),2-alpha,3-beta,4a-beta,8a-alpha)- |
| terpentecin |
| antibiotic mf 730n6 |
| mf 730n6 |
| 100440-25-3 |
| CHEBI:50301 |
| [(2s)-2-{(1r)-1-hydroxy-2-[(1s,2s,3r,4as,8as)-3-hydroxy-1,2,4a,5-tetramethyl-4-oxo-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl]ethyl}oxiran-2-yl](oxo)acetaldehyde |
| LMPR0104040002 |
| 2-[(2s)-2-[(1r)-2-[(1s,2s,3r,4as,8as)-3-hydroxy-1,2,4a,5-tetramethyl-4-oxo-3,7,8,8a-tetrahydro-2h-naphthalen-1-yl]-1-hydroxyethyl]oxiran-2-yl]-2-oxoacetaldehyde |
| uct4-a |
| SCHEMBL93525 |
| C21093 |
| Q27122026 |
| {2-[1-hydroxy-2-(3-hydroxy-1,2,4a,5-tetramethyl-4-oxo-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl)ethyl]oxiran-2-yl}(oxo)acetaldehyde |
| DTXSID60905502 |
| AKOS040754160 |
Research Excerpts
Actions
| Excerpt | Reference | Relevance |
|---|---|---|
| "Terpentecin at a lower concentration (0.07 micrograms/ml) inhibited growth in vitro of mouse leukemia L1210 cells by 50%." | ( Terpentecin, an inhibitor of DNA synthesis. Hori, M; Isshiki, K; Sakata, N; Sawa, T; Takeuchi, T; Tamamura, T; Tsuchiya, M, 1988) | 2.44 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (4)
| Class | Description |
|---|---|
| diterpenoid | Any terpenoid derived from a diterpene. The term includes compounds in which the C20 skeleton of the parent diterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). |
| carbocyclic antibiotic | |
| octahydronaphthalenes | Any carbobycyclic compound that is an octahydronaphthalene or a compound obtained from an octahydronaphthalene by formal substitution of one or more hydrogens. |
| secondary alpha-hydroxy ketone | An alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing one hydrogen and one organyl group. Secondary alpha-hydroxy ketones are also known as acyloins, and are formally derived from reductive coupling of two carboxylic acid groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (14)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (28.57) | 18.7374 |
| 1990's | 6 (42.86) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.68
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.68) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (7.14%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (92.86%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||